Unraveling the Growth Hormone Secretagogue Receptor Family and Its Ligands
Background
The Growth Hormone Secretagogue Receptor (GHS-R) family plays a pivotal role in regulating growth hormone (GH) release, which is essential for growth, metabolism, and body composition. Understanding these receptors and their activators is crucial for developing therapeutic strategies for various conditions. This foundational review aims to comprehensively characterize the known members and ligands of the GHS-R family as understood in 2001.
Results
The review identified GHS-R1a as the primary functional receptor responsible for mediating the effects of ghrelin (the endogenous ligand) and various synthetic growth hormone secretagogues. It detailed the molecular structure of GHS-R1a, highlighting its characteristic seven transmembrane domains typical of G protein-coupled receptors. The authors elucidated a diverse array of both endogenous ligands (like ghrelin) and synthetic ligands (such as MK-0677 and GHRP-6), describing their known binding affinities and signaling pathways. > The paper established a foundational understanding of the GHS-R system, underscoring its critical role in regulating growth hormone secretion and its broader implications for metabolic regulation. They also discussed the existence of splice variants and other potential receptor subtypes, though their precise physiological significance was less clear at the time.
Why It Matters
This foundational review consolidated critical knowledge about the GHS-R system, providing a robust framework that significantly influenced subsequent research and drug discovery efforts. It highlighted the immense potential of targeting these receptors for therapeutic interventions in conditions such as growth hormone deficiency, cachexia (muscle wasting), and various metabolic disorders. The insights gained from this work were instrumental in driving the development of novel GHS-R agonists and antagonists for potential clinical applications. Future steps included more detailed characterization of receptor signaling pathways and the initiation of human trials for promising secretagogues.